• INNOVATION PARTNERS LLC announces the appointment of Grace DiBonaventura Beyer, Executive Director, Market Research, and Kayla Thomas, Executive Assistant

    EXCELSIOR, MN – April 6, 2022 – INNOVATION PARTNERS LLC today announced the appointment of Grace DiBonaventura Beyer, Executive Director, Market Research and Kayla Thomas, Executive Assistant, in April of 2022. Grace DiBonaventura Beyer comes to Innovation Partners with 30+ years of pharmaceutical and healthcare research experience with 15 years experience focused in oncology, hematology, ...

    Read More
  • INNOVATION PARTNERS, LLC announces the appointment of Melinda Algera, Executive Director, Market Access Strategy, and Nancy Danielson, Chief Financial Officer

    EXCELSIOR, MN – January 12, 2022 – INNOVATION PARTNERS LLC today announced the appointment of Melinda Algera, Executive Director, Market Access Strategy, and Nancy Danielson, Chief Financial Officer, in January of 2022.   Melinda Algera comes to Innovation Partners with 26 years of pharmaceutical industry experience with the past 13 years focused specifically in oncology, hematology and rare disease. Through her pervious roles at Merck, ...

    Read More
  • COVID-19 Therapeutics and More

    The U.S. Department of Justice gave the green light for six pharmaceutical companies to share manufacturing data in the quest for COVID-19 therapeutics. The companies may not, however, share pricing information and production costs. And changes are happening in the world of oncology from a new editor at the helm of the Journal of Clinical ...

    Read More
  • Novartis Q2 Sales Down, Pfizer and BioNTech Prepare for COVID-19 Vaccine Testing

    This week's Innovation Partners BioBlog contains several updates from major players in the pharmaceutical industry. Novartis' sales dropped in the second quarter after early pandemic drug stockpiling boosted Q1 sales. The company is also struggling with unanticipated and serious side effects reported for its macular degeneration drug, Beovu. Pfizer and BioNTech are preparing for late-stage ...

    Read More
  • A COVID-19 Vaccine by Early 2021?

    U.S. health officials stated they expect to have 300 million doses of a vaccine for the novel coronavirus by early 2021 despite the fact that a final vaccine candidate has not been chosen. NCCN makes the case for biosimilars to help in the fight against cancer, and Roche is set to pay $775 million for ...

    Read More
  • Are We Close to a COVID-19 Vaccine Yet?

    In this week’s Innovation Partners BioBlog, we take a look at several updates from companies and groups working on treatments and vaccines for the novel coronavirus. A bipartisan group seeks to protect hospitals from losing their 340B status due to lower inpatient hospital admissions from specific groups during the COVID-19 outbreak. And lawmakers continue to ...

    Read More
  • Drug Prices Rise Despite the Pandemic; SCOTUS Takes on the ACA

    Happy Independence Day to all of our American readers! In this week’s Innovation Partners BioBlog, we take a look at several updates from the pharmaceutical world. AstraZeneca is the first company to participate in a new FDA program to disclose all patient-reported symptoms during drug trials. The Trump administration is asking SCOTUS to weigh in ...

    Read More
  • Breakthroughs in Cancer Testing and Treatment

    Breakthroughs announced this week at the AACR Virtual Meeting show that the pace of cancer diagnosis, testing, and treatment hasn't slowed despite the worldwide pandemic. Clinical trials of a new personalized cancer vaccine show promise, while researchers appear to have developed a blood test that can correctly identify types of brain tumors. There's also good ...

    Read More
  • Oncology Update

    This week’s Innovation Partners BioBlog focuses on oncology updates. NICE backs funding for Roche’s lung cancer drug, Rozlytrek, after the company offers discounts. New personalized oncology treatments may be available based on patients’ genetic profiles thanks to a partnership between MD Anderson and Philips. More stories in this week’s Innovation Partners BioBlog. NICE backs funding ...

    Read More
  • The Quest for a COVID-19 Therapy

    In this week’s edition of the Innovation Partners BioBlog, we look at two stories related to pharmaceutical giant AstraZeneca. AstraZeneca has identified two potential antibodies against COVID-19 and expect to move them into the clinic by August. However, this means that AstraZeneca’s merger with Gilead is off the table for now as the company focuses ...

    Read More